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Abstract
DNA methylation and histone acetylation are two well known epigenetic chromatin modifications.
Epigenetic agents leading to DNA hypomethylation and histone hyperacetylation have been
approved for treatment of hematological disorders. The first histone deacetylase inhibitor,
vorinostat, has been licensed for cutaneous T cell lymphoma treatment. More than 11 new
epigenetic agents are in various stages of clinical development for therapy of multiple cancer types.
In this review we summarize novel histone deacetylase inhibitors and new regimens from clinical
trials for epigenetic therapy of cancer.
Introduction
DNA methylation and histone acetylation are two most
studied epigenetic modifications, although ethyl, acetyl,
phosphoryl, and other modifications of histones have
been described [1,2]. Histone acetylation and methyla-
tion have been studied extensively in carcinogenesis [3].
Histone acetylases (HATs), histone deacetylases
(HDACs), histone lysine methyltransferases (HMTs), and
histone demethylases are key enzymes involved in epige-
netic regulation and chromatin remodeling. Coordinated
DNA methylation and histone modification play a key
role in the control of gene expression [2]. Vorinostat
(Zolinza, Merck) is the first HDAC inhibitor that has been
licensed for clinical use [4-10]. More than 11 HDAC
inhibitors are in clinical development. In this review we
summarize novel HDAC inhibitors and new regimens
from clinical trials for epigenetic therapy of cancer.
Vorinostat (SAHA, Zolinza)
Eighteen enzymes from HDAC family have been identi-
fied in human [4,11-14]. Voriniostat (formerly, suberoy-
lanilide hydroxamine, SAHA) is a pan-HDAC inhibitor
[4,14]. SAHA has significant anti-cancer activity in a wide
range of cancers [4,14-17]. Vorinostat (VOR) was studied
in a phase II trial for patients with refractory cutaneous T-
cell lymphoma (CTCL) [4,15-18]. 33 patients who have
failed a median of 5 prior therapies were enrolled. Similar
to other epigenetic agents, time to response to SAHA was
11.9 weeks. SAHA is well tolerated orally with common
toxicities including fatigue, thrombocytopenia, nausea
and diarrhea. 200 mg BID orally has the most favorable
safety and efficacy profile [4,15-18]. A separate phase IIb
trial which included 74 patients with refractory or persist-
ent CTCL confirmed the activity of VOR [19,20]. 32% of
the patients also had pruritus symptom relief. Pulmonary
embolism was reported in 5% of the patients. VOR has
been approved for treatment of refractory CTCL (Zolinza,
Merck). Since then there have been more than 30 trials
testing VOR in single agent or in combination (Table 1
and 2). In an analysis reported at the American society of
Clinical Oncology (ASCO) 2008 annual meeting, 476
patients received VOR either as single agent or combined
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Table 1: Vorinostat in single agent trials
HDACI Disease Dose & schedule Phase No. Pts Outcome Reference
Vorinostat Various cancer 400 mg, oral I 476 Tolerated, safe [21]




Vorinostat GI cancer 300 mg Bid PO 3 days/w q21d II 16 safe, PK results [26]
Vorinostat TCC 200 mg Bid PO II 14 study closed [36]
Vorinostat Breast, colon, lung Cancer 200–400 mg Bid PO ×14q21d II 16 SD: 50% [22]
Vorinostat MM 200–300 mg Bid PO × 5d/wq28d/200–400 
mg Bid PO × 14d/wq21d
I 13 No response [40]
Vorinostat DLBCL 300 mg Bid PO 3 days/week II 18 CR: 5.5%
SD: 5.5%
[23]
Vorinostat Gynecologic tumor 400 mg/d PO II 27 Insufficient activity (PR: 3%) [37]
Vorinostat MDS, leukemia 100–300 mg Bid/TidPO ×14q21d 1 41 MTD:200 mg Bid [24]
Vorinostat Head neck cancer 400 mg qd PO II 12 No response [41]
Vorinostat mesothelioma NR I 13 PR: 15% [35]
CR: complete responses; PR: partial response; SD: stable disease. MTD: maximal tolerated dose; NR: not reported.
Table 2: Vorinostat in combination trials
HDACI Other agent Disease Dosage Phase Pts No Response Reference
Vorinostat capecitabine Solid tumors VOR:300–400 mg/d PO
CAP:750–1000 mg bid PO




Vorinostat bevacizumab kidney cancer VOR:200 mg BID × 14 d PO
BEV:15 mg/kg, q21div
I 8 SD: 42% [27]
Vorinostat bexarotene CTCL VOR:300–400 mgqdPOq28d
BEX:150–300 mg/m2qdq28d




Vorinostat tamoxifen breast cancer VOR:400 mg/d ×21d PO
T AM:20 mg/d PO








C BP:5.0AUC, iv/CDDP:75 
mg/m2, iv d3
I1 2 P R :  5 7 %
SD: 28%
[38]
Vorinostat 13-cis-retinoid acid Pediatric CNS,
solid tumors
VOR:180–230 mg/m2 po qd
13cRA: 80 mg/m2po bid
I 13 MTD: VOR 180 mg/m2/d × 4/w
13cRA: 80 mg/m2bid
[39]
Vorinostat Carboplatin Paclitaxel solid tumors VOR:400–600 mg/d PO 
q21d
C BP:6.0 AUC, iv
PTX:200 mg/m2, iv
I2 8 P R :  4 4 %
SD: 28%
[34]
Vorinostat bortezomib MM VOR:100–400 mg PO d4–11
VEL:1.3 mg/m2 IV d1, 4, 8 
and 11
I 23 MTD: VOR 400 mg d 4–
11;VEL1.3 mg/m2d1, 4, 8, 11.
[25]
VEL: bortezomib; CR: complete responses; PR: partial response; SD: stable disease. MTD: maximal tolerated dose;Journal of Hematology & Oncology 2009, 2:22 http://www.jhoonline.org/content/2/1/22
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with another agent [21]. More than half of those patients
had fatigue, nausea and diarrhea. Dose modifications
were not required nevertheless in the majority of the
patients.
In a multicenter phase II single agent study, 16 patients
with breast, colon and lung cancers received VOR at doses
of 200, 300, and 400 mg BID for 14 days out of every 3
weeks. Disease stabilization was observed in half of the
patients, but there were no confirmed responses [22].
In a single agent phase I study of VOR for patients with
recurrent diffuse large B-cell lymphoma, 2 of the 18
enrolled patients had response, the other 16 had disease
progression [23]. 300 mg BID 3 days/week was well toler-
ated but with limited activity.
Single agent VOR was also investigated in a phase I study
for patients with leukemia and myelodysplasia (MDS)
[24]. Thirty one of the 41 patients enrolled had acute mye-
loid leukemia (AML). VOR was given twice or thrice daily
for 14 days with dose range of 100–300 mg in a 21-day
cycle. The Maximal tolerated dose (MTD) was 200 mg
BID. Seven patients had hematological improvement,
including 4 AML with complete responses. Increased his-
tone acetylation was seen at all dose levels.
VOR was combined with bortezomib in a phase I trial for
patients with relapsed or refractory multiple myeloma
(MM) [25]. The dose limiting toxicity (DLT) was QT pro-
longation and fatigue. The MTD was VOR 400 mg on days
4–11 and bortezomib 1.3 mg/m2 on day 1, 4, 8, 11.
In a phase I trial for Japanese patients with gastrointestinal
cancer, DLT of single agent VOR was grade 4 thrombocy-
topenia [26]. In this group of 16 Japanese patients, 300
mg BID for 3 consecutive days followed by a 4-day rest
each week was the tolerable regimen.
In a small phase I study of patients with stage IV renal cell
carcinoma, VOR 200 mg BID × 14 days was combined
with bevacizumab 15 mg/kg on a 21-day cycle [27]. Eight
patients were enrolled. Severe thrombocytopenia was the
DLT at the above dosing schedules (MTD). Phase II study
is underway.
In a preliminary report of a phase I dose-escalating trial of
VOR plus bexarotene for advanced CTCL, 19 patients were
included [28]. MTD was not reached yet. 1 patient had a
CR, 3 had a PR, and 12 had stable disease.
HDAC inhibitors have been reported to restore hormone
sensitivity of estrogen and progesterone receptors [29-31].
VOR 400 mg daily × 3 weeks was combined with daily
tamoxifen in a 4-week cycle for patients with hormone-
refractory breast cancer [32]. 17 of the 19 enrolled
patients were evaluable. Four patients had objective
response, one of them was in CR. H3 and H4 histone
acetylation was seen at day 8. These findings imply that
VOR may restore hormone sensitivity in hormone-refrac-
tory breast cancer patients.
VOR was investigated in combination with capecitabine
(CAP) in a phase I/II trial for patients with advanced solid
tumors [33]. Twenty eight patients were in phase I, 14
patients were in phase II. The phase II regimen was VOR
300 mg daily plus CAP 1000 mg BID × 14 days per 21 day
cycle. Preliminary results appeared to be encouraging.
In another phase I trial for patients with advanced solid
tumors, VOR was combined with carboplatin (AUC = 6)
and paclitaxel (200 mg/m2) [34]. VOR was given as 400
mg daily × 14 days or 300 mg BID × 7 days in a 3-week
cycle. Twenty five of the 28 patients enrolled were evalua-
ble. The DLT was emesis and neutropenia. 11 patients had
PR, 7 patients had stable disease. Both VOR dosing sched-
ule was well tolerated in combination.
Advanced mesothelioma progressed after first-line chem-
otherapy has poor prognosis. thirteen such patients were
included in a single agent phase I trial [35]. Two patients
had a partial response. This was considered to be promis-
ing for these poor-prognostic patients. A randomized
phase III trial of oral VOR for patients with advanced mes-
othelioma are underway.
VOR 200 mg BID was also evaluated in a single agent
phase II study for patients with recurrent/metastatic tran-
sitional cell carcinoma who failed platinum therapy [36].
Fourteen patients were included in the report at ASCO
2008 meeting. Two early on-study death was reported,
and the study was closed to further accrual.
Single agent VOR at 400 mg daily had disappointing
results in a phase II study for patients with platinum-
resistant ovarian or primary peritoneal carcinoma [37].
VOR is also being studied in several phase I studies with a
variety of regimens including gemcitabine/cisplatin for
lung cancer, 13 cis-retinoic acid for children with solid
tumors (Table 1 and 2) [38,39]. Final results are awaited.
Single agent VOR for solid tumors and MM was overall
disappointing in early clinical trials [22,37,40,41].
New HDAC inhibitors
HDAC inhibitors generally consist of three parts in the
chemical structure: (1) a zinc-chelating group; (2) a spacer
group, which is generally hydrophobic; and (3) an
"enzyme binding" group that confers specificity and is
generally aromatic in character [42]. A spectrum of natu-
rally occurring or synthetic HDAC inhibitors have beenJournal of Hematology & Oncology 2009, 2:22 http://www.jhoonline.org/content/2/1/22
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Table 3: New HDAC inhibitors in clinical trials
HDACI Other agents Dose & schedule disease Phase Pts No Outcome Reference
CI-994 capecitabine 4–6 mg/m2 solid tumors I 54 MTD:6 mg/m2 [49,50]
CI-994 gemcitabine 2–8 mg/m2 po qd solid tumors I 20 MTD:6 mg/m2+
Gem1000 mg/m2
[47]
CI-994 paclitaxel carboplatin 4–6 mg/m2 solid tumors I 30 MTD: 4 mg/m2 [48]
CI-994 8 mg/m2 po qd solid tumors I/II 53 MTD:8 mg/m2 [46]
FK228 gemcitabine 7–12 mg/m2 Pancreatic, Solid tumors I 33 MTD: 12 mg/m2+
Gem 800 mg/m2
[53]
FK228 1–9 mg/m2 thyroid, Solid tumors I 26 MTD: 9 mg/m2 [54]
FK228 18 mg/m2i.v. d1 & d5, q3w MDS, AML II 12 CR: 8%
SD: 50%
[55]
FK228 17.8 mg/m2 d1 & d7, q 3w lung cancer II 19 No response [56]
FK228 14 mg/m2 i.v.d1, 8, 15 q4w T-cell lymphoma II 42 no myocardial
damage
[58]
FK228 13 mg/m2 i.v.d 1, 8, 15, 
q4w
Kidney CA II 29 Insufficient activity
(7% RR)
[57]
ITF2357 150 mg or 100 mgQ12 h 
4 d
MM II 16 PR: 6% SD: 31% [61]
ITF2357 100 mg PO Hodgkins II 15 SD: 54% [60]
LBH589 Docetaxel
prednisone
15–20 mg po qod CRPC I 16 Oral study closed.
IV form ongoing
[64]
LBH589 20 mg day 1, 3 5 CTCL II 40 RR: 12% [65]
LBH589 4.8–11.5 mg/m2 IV Hematological neoplasms I 15 Study halted due to
QTc prolongation
[63]
MGCD0103 gemcitabine Phase I: 50–110 mg
Phase II: 90 mg
solid tumors I/II 29 MTD: 90 mg [70]
MGCD0103 12.5–56 mg/m2/d solid tumors I 38 MTD: 45 mg/m2 [68]
MGCD0103 20–80 mg/m2 leukemia I 29 MTD: 60 mg/m2 [69]
MGCD0103 85 mg, 110 mg NHL II 50 RR: 23% [71]
MGCD0103 85 mg, 110 mg HL II 33 RR: 38% [72]
MS-275 4–10 mg/m2 leukemia I 38 MTD:8 mg/m2 [75]
MS-275 4–6 mg/m2 Solidtumors, lymphoma I 27 MTD:6 mg/m2 [76]
MS-275 3–7 mg/m2 melanoma II 28 SD: 21–29% [77]
PCI-24781 2.0–2.4 mg/kg solid tumors I 15 MTD: pending [49]
PBA 9–45 g/d solid tumors I 28 MTD:27 g/day [82]
PBA 150–515 mg/kg/d solid tumors I 24 MTD:410 mg/kg [81]
PBA 60 mg -360 mg/kg/d solid tumors I 21 MTD:300 mg/kg [80]
PBA 5-FU 410 mg/kg/d colorectal cancer I 9 MTD: Not reported [83]
PBA azacitidine 200 mg/kg/d AML MDS II 10 RR:50% [84]
PXD101 1000 mg/m2/d ×5 Ovarian ca II 30 SD: 60% [88]
PXD101 600, 900, 1000 mg/m2/day Hematological neoplasms I 16 MTD: 1000 mg/m2/day [87]
PXD101 150–1200 mg/m2/day solid tumors I 46 MTD: 1000 mg/m2/day [86]
VPA 30–120 mg kg(-1) day(-1) 
IV × 5
solid tumors I 26 MTD: 60 mg/kg/day [93]
VPA ATRA serum level 50–100 mcg/
ml
AML II 58 RR: 5% (not active) [90]
VPA ATRA 5–10 mg/kg AML I 26 Insufficient activity [91]
VPA 20 – 40 mg/kg/d × 5 Cervical ca I 12 MTD: Not reported [92]
HDAC: histone deacetylase inhibitor; CR: complete responses; PR: partial response; SD: stable disease. MTD: maximal tolerated dose; RR: 
response rateJournal of Hematology & Oncology 2009, 2:22 http://www.jhoonline.org/content/2/1/22
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characterized for their antitumor activities in preclinical
studies [43]. Six major classes of HDAC inhibitors have
been defined on the chemical structures [44]. These
include short-chain fatty acids (butyrate and valproic
acid), hydroxamates (SAHA, trichostatin A, ITF2357,
LBH589, oxamflatin, PCI-24781, and PXD101), benza-
mides (MS-275, CI-994, and MGCD-0103), cyclic
tetrapeptides (depsipeptide, trapoxin A, and apicidin),
electrophilic ketones (trifluoromethylketone), and mis-
cellaneous (depudecin, SNDX-275, and isothiocyanates).
In addition to vorinostat which has been approved for
clinical treatment of advanced CTCL, there are at least 11
more HDAC inhibitors in various stages of clinical devel-
opment (Table 3).
1. CI-994 (N-acetyldinaline, [4-(acetylamino)-N-(2-amino-phenyl) 
benzamide])
CI-994 is an orally active HDAC inhibitor that belongs to
the benzamide class [45]. A phase I/II study was carried
out in patients with solid tumors. Fifty three patients
received CI-994 orally for 2–10 weeks [46]. Thrombocyto-
penia was the DLT. The MTD was 8 mg/m2/day for 8
weeks. One refractory lung cancer patient had PR for over
2 years, 3 additional patients had stable disease.
CI-994 was investigated in combination with gemcitabine
in a phase I trial for solid tumors [47]. Twenty patients
were treated with gemcitabine (1000 mg/m2 on days 1, 8,
15). CI-994 was given orally in a dose-escalating schedule
from 2–8 mg/m2/day in a 21-day cycle. The DLT was
thrombocytopenia, and the MTD was 6 mg/m2 for combi-
nation with gemcitabine. CI-994 was also studied in com-
bination with paclitaxel and carboplatin in a phase I trial
in patients with advanced solid tumors [48]. CI-994 dose
ranged 4–6 mg/m2 for one or two weeks. Thirty patients
were enrolled. The MTD was 4 mg/m2 for 7 days for the
combination regimen. CI-994 was evaluated in another
phase I trial in combination with capecitabine [49,50].
Fifty four patients with advanced solid tumors were
enrolled. CI-994 was given in a dose-escalating schedule
from 4–6 mg/m2 daily. The DLT was thrombocytopenia.
The MTD was 6 mg/m2 daily for two weeks in a 21-day
cycle in combination with capecitabine.
2. FK228 (FR901228, depsipeptide, romidepsin)
FK 228 is a potent bicyclic depsipeptide and a novel
HDAC inhibitor [51,52].
FK228 was studied in combination with gemcitabine in a
phase I trial for patients with advanced solid tumors [53].
Thirty three patients were included in the report. Non-
hematologic toxicities have been mild to moderate nau-
sea, vomiting, and fatigue. The recommended phase II
dose schedule is FK228 (romidepsin) 12 mg/m2 and gem-
citabine 800 mg/m2 every other week.
HDAC inhibitors restore expression of the sodium iodine
symporter in refractory cells and sensitivity to RAI in vitro.
A phase I trial was conducted for patients with thyroid and
other advanced cancers using FK228 (romidepsin) on
days 1, 3, 5 [54]. Twenty six patients were enrolled. Severe
adverse events were hematologic and GI toxicities. The
MTD is 9 mg/m2. Histone acetylation was shown to have
a greater than 2-fold increase. This study was planned to
focus exclusively on non-medullary thyroid cancer.
FK228 (depsipeptide) was also evaluated in a phase II
study for patients with high risk MDS and AML [55].
FK228 was given on day 1 and day 8 to 12 patients at 18
mg/m2 over a 4-hour infusion every 3 weeks. There was
one CR, six stable diseases. Histone H3 and H4 acetyla-
tion was seen, but there was no consistent changes.
Another phase II trial of FK228 was done in patients with
refractory lung cancer [56]. Nineteen patients were treated
on day 1 and 7 every 3 weeks at a dose of 17.8 mg/m2.
Hematologic toxicity was dose-limiting in one patient, no
objective responses were observed in this single agent
study.
In another single-agent phase II trial, FK228 was given to
patients with refractory metastatic renal cell carcinoma at
13 mg/m2 on days 1, 8, and 15 of a 28-day cycle [57].
Twenty nine patients were enrolled. Four patients had
severe cardiac toxicity with one sudden death. There was
only a 7% overall response rate. The study was closed due
to insufficient efficacy. In a separate study with detailed
monitoring of cardiac toxicities in 42 patients with T-cell
lymphoma, Fk228 was given at 14 mg/m2 on days 1, 8,
and 15 of a 28-day cycle [58]. FK228 was not found to be
associated with myocardial damage or decrease in cardiac
function even though EKG changes with T-wave flattening
or ST-segment depression were observed. The cardiac tox-
icities are believed to be a class effect of HDAC inhibitors.
3. ITF2357
ITF2357 is an orally effective member of hydroxamic fam-
ily of HDAC inhibitors and can reduce production of
inflammatory cytokines [59]. ITF2357 was investigated in
an Italian phase II trial on patients with heavily pretreated
refractory Hodgkin's disease [60]. ITF2357 was given at
100 mg PO daily. Fifteen patients were enrolled, 13 were
evaluable for responses. Stable diseases were seen in seven
(54%) patients. 20% of the patients had QTc interval pro-
longation prompting transient drug discontinuation.
Overall it was reported to be well tolerated.
A phase II study reported at ASH 2007 annual meeting
administered 150 mg or 100 mg of ITF2357 orally every
12 hours for four consecutive days followed by a 3 day rest
every week of a 28-day cycle [61]. Sixteen patients withJournal of Hematology & Oncology 2009, 2:22 http://www.jhoonline.org/content/2/1/22
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refractory MM were treated. The most common grade 3–4
toxicities were GI side effects, neutropenia, and thrombo-
cytopenia. Three patients had abnormal EKG changes.
One patient achieved partial response, and five others had
stable diseases.
4. LBH589 (panobinostat)
LBH589 is a novel pan-HDAC inhibitor. Treatment with
LBH589 not only has been shown to induce acetylation of
histones, induction of p21, cell cycle growth arrest, and
apoptosis but also has been demonstrated to induce
acetylation of HSP90 [62].
LBH589 IV formulation was investigated in a phase I trial
for patients with refractory hematological malignancies
[63]. LBH589 as a single agent was administered as a 30-
minute i.v. infusion once daily on days 1 to 7 of a 21-day
cycle. The doses ranged from 4.8 mg/m2 to 14 mg/m2. 15
patients were enrolled. The DLT was QTc prolongation at
14 mg/m2. A significant increase in acetylation of the H2B
and H3 histones in the leukemic blast (CD34+) cells is
consistent with LBH589 reaching its target. The study was
halted due to safety concerns about QTc prolongation.
Oral LBH589 was studied alone and in combination with
docetaxel and prednisone in castration-resistant prostate
cancer [64]. 20 mg of oral LBH589 was administered on
days 1, 3 and 5 for 2-week on and 1-week off schedule for
LBH589 alone arm, 15 mg of LBH589 was given follow-
ing the same schedule in the combination arm. Eight
patients were enrolled into each arm. There was no appar-
ent synergistic effect in the combination arm. Three
patients achieved PR as the best responses. This study was
closed and further clinical trials are being focused on IV
formulation which produces higher peak concentration
with comparable toxicity profile.
LBH589 was tested in a phase II trial in patients with
CTCL [65]. LBH589 was administered orally at 20 mg on
days 1, 3, and 5 weekly until disease progression. Patients
with cardiovascular abnormalities or QTc>450 msec were
excluded. Intensive ECG monitoring was performed. 40
patients have been enrolled in the report. Five patients
achieved skin response including one complete skin
response. Another patient with PD improved to PR after
initial flaring of disease. There was no QTc>500 ms
observed.
5. MGCD0103
MGCD0103 is a selective orally available benzamide
HDAC inhibitor that targets HDAC 1, 2, 3 (class 1) and 11
(class 4) [66,67]. It avoids the class 2 enzymes.
MGCD0103 was studied in a phase I trial for patients with
advanced solid tumors. It was administered orally three-
times-per-week for 2 of every 3 weeks [68]. The dose
ranges were from 12.5 mg to 56 mg/m2 in 38 patients over
99 cycles. The DLT included fatigue, nausea, vomiting,
and diarrhea. The recommended phase II dose was 45 mg/
m2/day. There was inhibition of HDAC activity and induc-
tion of acetylation of H3 histones by MGCD0103.
A separate phase 1 trial of oral MGCD0103 was conducted
in patients with leukemia and myelodysplastic syndromes
[69]. MGCD0103 was administered orally 3 times weekly
without interruption. Twenty-nine patients with a median
age of 62 years (32–84 years) were enrolled at dose levels
of 20–80 mg/m2. The DLT were similar to those reported
from the previous study [68]. The maximum tolerated
dose was determined to be 60 mg/m2. Three patients
achieved a complete bone marrow response.
MGCD0103 was also evaluated in a phase I/II trial in
combination with gemcitabine in patients with solid
tumors [70]. Twenty-nine patients were enrolled (25 in
phase I, 4 in phase II). Dose levels of MGCD0103 ranged
between 50 and 110 mg. The MTD and recommended
phase II dose was 90 mg. 2 of 5 pancreatic cancer patients
achieved PR. Phase II at 90 mg MGCD0103 3 ×/week plus
gemcitabine 100 mg/m2 weekly × 3 per 4-week cycle is
ongoing for pancreatic cancer patients.
A phase II trial of oral MGCD0103 was conducted in
patients with refractory large B-cell (DLBCL) or follicular
lymphoma [71]. Among 50 patients enrolled, 32 patients
received 110 mg three times per week. The dose was
reduced to 85 mg 3 ×/week afterwards. 1 CR and 3 PRs
with a response rate of 23.5% were achieved in 17 patients
with DLBCL. Inhibition of HDAC activity was seen in 13
of 18 patients evaluated. In a separate phase II study,
patients with refractory Hodgkin lymphoma were
enrolled for treatment with MGCD0103 [72]. Twenty
three patients received 110 mg, 10 patients had 85 mg 3
×/week in 4-week cycles. Most patients had failed prior
autologous transplants. Among the 110 mg cohorts, 2
patients achieved CR, 6 achieved PR, for an overall
response rate of 38%. The median time to response was 2
cycles. The 85 mg dose was better tolerated and further
study at this dose level is ongoing.
6. MS-275 (MS-27–275; N-(2-aminophenyl)-4-[N-(pyridin-3-yl-
methoxycarbonyl) aminomethyl] benzamide)
MS-275 is a novel synthetic benzamide derivative that has
been shown to inhibit HDAC activity [73,74]. A phase I
dose-escalating study has been completed in patients with
advanced acute leukemia [75]. Thirty eight patients were
enrolled. The first 13 patients were treated with MS-275
initially once weekly × 2, repeated every 4 weeks from 4 to
8 mg/m2. The rest of the patients were treated once weekly
× 4, repeated every 6 weeks from 8 to 10 mg/m2. The MTDJournal of Hematology & Oncology 2009, 2:22 http://www.jhoonline.org/content/2/1/22
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was 8 mg/m2 weekly for 4 weeks in 6-week cycle. The DLTs
included infections and neurologic toxicity manifesting as
unsteady gait and somnolence. MS-275 induced H3 and
H4 acetylation.
MS-275 was also investigated in patients with solid
tumors in a phase I trial [76]. Twenty seven patients with
advanced solid malignancies and lymphomas were
treated on three dose schedules. MS-275 is well tolerated
at doses up to 6 mg/m2 every other week or 4 mg/m2
weekly for 3 weeks. The DLTs were hypophosphatemia
and asthenia on the weekly and twice-weekly dosing
schedules; there was no dose-limiting toxicity on the every
other week schedule. Four mg/m2 given weekly for 3
weeks every 28 days were recommended for phase II
study.
A phase II trial was done on patients with refractory met-
astatic melanoma [77]. Twenty eight patients were rand-
omized to receive MS-275 3 mg biweekly (days 1+15, arm
A) or 7 mg weekly (days 1+8+15, arm B), in 4-week cycles.
Nausea and hypophosphatemia were the most common
toxicities. No objective response was reported. Stable dis-
ease was observed (29% in Arm A, 21% in Arm B). Single
agent MS-275 appears to be ineffective in this population
of patients.
7. PCI-24781 (CRA-024781)
PCI-24781 is a novel, broad spectrum hydroxamate-based
inhibitor of HDAC that shows preclinical antitumor activ-
ity [78]. A phase I study was done in patients with solid
tumors [49]. 15 patients were reported at the ASCO 2008
annual meeting. Intravenous and oral forms are both
studied. Tubulin and histone acetylation were measured
in peripheral blood mononuclear cells. Hematologic and
GI toxicities were observed, and 1 patient had EKG
changes. Acetylation levels increased at 1.5 hour post dose
and sustained through 4 hours in all patients and up to 24
hours in 60% of the patients. PCI-24781 was well toler-
ated following IV administration. Further study of oral
formulation is ongoing.
8. Phenylbutyrate
Phenylbutyrate (PBA) is an aromatic short-chain fatty acid
that has activity in HDAC inhibition [79]. Phase I clinical
studies have been done [80-82]. Oral PBA was evaluated
in a phase I trial [82]. Twenty eight patients with refractory
solid tumors were included. Five dose levels (9 gm/day to
36 gm/day in three divided doses) were studied. The DLTs
were nausea, vomiting and hypocalcemia at 36 gm/day.
27 gm/day was the recommended phase II dose. PBA was
administered intravenously as 120-hour infusion in 24
patients with solid tumors in a separate phase I trial [81].
Six dose levels were studied (150 mg to 515 mg/kg/day in
21-day cycles). The DLTs were mainly neurological, such
as somnolence and confusion. The MTD was 410 mg/kg/
day for 5 days. Another phase I trial evaluated twice-daily
PBA infusions for two consecutive weeks every month at
five doses levels (60 mg -360 mg/kg/day) in patients with
advanced solid tumors [80]. The MTD was 300 mg/kg/
day.
PBA was also studied in combination with 5-fluouracil
(FU) in a phase I trial. FU (24-hour continuous intrave-
nous infusion (CIV)) with dose escalation (2–2.3 g/m2),
in combination with PB (120 hour CIV at fixed dose 410
mg/kg/d × 5) was administered weekly in patients with
advanced colorectal cancer [83]. Nine patients were
enrolled. MTD has not been reached at the time of report.
PBA was also combined with azacitidine in a phase II trial
for patients with AML and MDS [84] (see above under sec-
tion of azacitidine).
9. PXD101 (belinostat)
PXD101 is a novel hydroxamate-type HDAC inhibitor
[43,85]. A phase I trial of PXD101 was performed on
patients with advanced solid tumors [86]. Forty six
patients were enrolled. 6 dose levels were tested. The DLT
were grade 3 fatigue. The MTD was determined to be 1000
mg/m2 IV infusion over 30 minutes daily for 5 days per
21-day cycle. Histone H4 hyperacetylation was observed
after each infusion and was sustained for 4 to 24 hours in
a dose-dependent manner. Of the patients treated at the
MTD, 50% achieved stable disease.
Another phase I dose-finding study was done in patients
with advanced hematological malignancies [87]. Sixteen
patients were enrolled. Four dose levels were included.
One patient developed drug-related grade 3 toxicities,
including fatigue and neurological symptoms. The MTD
was same as above and was to be used for phase II studies.
One phase II study of PXD101 was reported at 2008
ASCO annual meeting [88]. In this study, 30 patients with
metastatic or recurrent and refractory ovarian cancer were
enrolled. Eighteen out of the 30 patients had stable dis-
eases. The study appears to be promising, and recruitment
was still ongoing.
10. Valproic acid
Valproic acid (VPA, 2-propylpentanoic acid) is a well
established drug for the therapy of epilepsy. It is tera-
togenic when administered during early pregnancy and
can induce birth defects such as neural tube closure
defects and other malformations. The well-tolerated
antiepileptic drug was found to be a powerful HDAC
inhibitor. VPA induces differentiation of carcinoma cells,
transformed hematopoietic progenitor cells and leukemic
blasts from acute myeloid leukemia patients [89].Journal of Hematology & Oncology 2009, 2:22 http://www.jhoonline.org/content/2/1/22
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VPA was studied in combination with All-trans retinoid
acid (ATRA) in patients with AML who were not candi-
dates for intensive chemotherapy [90]. Fifty eight patients
were enrolled. Forty patients received the combination
therapy. There was only 5% response rate for this group of
patients with no CR observed. Another trial of VPA (5–10
mg/kg) plus ATRA (45 mg/m2) was done on 26 patients
with poor-risk AML [91]. No patients achieved CR. These
studies suggest that additional trials are needed to clearly
define the activity of VPA in poor-risk AML patients.
A phase I trial of single agent VPA was reported in patients
with newly diagnosed cervical cancer [92]. Twelve patients
were included. VPA doses ranged from 20 mg/kg to 40
mg/kg daily for 5 days. The most common side effect was
depressed level of consciousness which was not severe.
Tumor HDAC activity decreased in 8 patients. However,
there was no correlation between H3 and H4 hyper-
acetylation with serum levels of VPA.
VPA was studied for IV administration in a phase I trial for
patients with advanced cancer [93]. Twenty six patients
were enrolled. VPA was administered as a 1-hour infusion
daily for 5 consecutive days in a 21-day cycle with doses
ranging between 30 mg/kg/day and 12 mg/kg/day. The
MTD was 60 mg/kg/day. The DLT was grade 3 or 4 neuro-
logical impairment occurring in 8 out of 26 patients.
11. Other HDAC inhibitors in early stage of clinical development 
(Isothiocyanates, NVP-LAQ824, SNDX-275)
Isothiocyanates (ITC) can be found as thioglucoside con-
jugates, i.e. glucosinolates, in a wide variety of cruciferous
vegetables including broccoli, cabbages, watercress, and
Brussel's sprouts, etc. A phase I study of glucosinolate and
ITCs (sulforaphane) were done in healthy volunteers [94].
The excretion of a metabolite, dithiocarbamates, was
measured. No clinically significant toxicities were
observed. Sulforaphane and phenylhexyl isothiocyanate
(PHI) are among the synthetic isothiocyanates that are
shown to be HDAC inhibitors and have antitumor activi-
ties in vitro and in vivo [95-100]. PHI was found recently
to have dual epigenetic effects as both HDAC inhibitor




propenamide) is a structurally novel hydroxamate deriva-
tive of HDAC inhibitors [101,102]. It has broad antitu-
mor activity in preclinical studies [103-106]. Clinical
trials in human are currently underway.
SNDX-275 is another novel HDAC inhibitor and is cur-
rently undergoing a phase I trial in combination with aza-
ciditine (see above under section of azacitidine).
There are more structurally novel HDAC inhibitors which
have been shown to have preclinical antitumor activities
[43]. Clinical developments are yet to be done.
Conclusion
Vorinostat is the first HDAC inhibitor that has been
approved for treatment of CTCL. More than 11 HDAC
inhibitors are in various stages of clinical development.
HDAC inhibitors may have more potential in the combi-
nation therapy of a wide range of malignancies. Combina-
tion of novel epigenetic agents, including
hypomethylating agents and HDAC inhibitors, and chem-
otherapeutic agents are being extensively investigated for
clinical treatment of malignant disorders. Results from the
clinical trials are eagerly awaited and being closed
watched.
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